6533b7cffe1ef96bd12590a7

RESEARCH PRODUCT

Does the renin-angiotensin system also regulate intra-ocular pressure?

Olli OksalaAnu VaajanenHeikki VapaataloSatu Luhtala

subject

medicine.medical_specialty030204 cardiovascular system & hematologyPeptide hormoneRenin-Angiotensin System03 medical and health sciences0302 clinical medicineInternal medicineRenin–angiotensin systemMedicineAnimalsHumansIntraocular Pressurebiologybusiness.industryAngiotensin-converting enzymeBiological activityGeneral MedicineWater-Electrolyte BalanceAngiotensin IIBiosynthetic PathwaysBlood pressureEndocrinologyACE inhibitorCirculatory system030221 ophthalmology & optometrybiology.proteinOcular Hypertensionbusinessmedicine.drug

description

The renin-angiotensin-aldosterone system is known to play an essential role in controlling sodium balance and body fluid volumes, and thus blood pressure. In addition to the circulating system which regulates urgent cardiovascular responses, a tissue-localized renin-angiotensin system (RAS) regulates long-term changes in various organs. Many recognized RAS components have also been identified in the human eye. The highly vasoconstrictive angiotensin II (Ang II) is considered the key peptide in the circulatory RAS. However, the ultimate effect of RAS activation at tissue level is more complex, being based not only on the biological activity of Ang II but also on the activities of other products of angiotensinogen metabolism, often exerting opposite effects to Ang II action. In recent studies, orally administered angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure (IOP), likewise topical application of these compounds, the effect being more prominent in ocular hypertensive eyes. Based on previous findings and our own experimental data, it can strongly be suggested that the RAS not only regulates blood pressure but is also involved in the regulation of IOP.

10.1080/07853890802043924https://pubmed.ncbi.nlm.nih.gov/19160528